J&J infectious news
Johnson & Johnson's Janssen pharmaceuticals units formed Janssen Global Public Health (GPH), which will be charged with R&D and delivery of medicines for resource-limited countries. Among the products to be included in the Janssen GPH portfolio are approved tuberculosis drug Sirturo bedaquiline; a long-acting injection of HIV drug rilpivirine (TMC2780LA), which is slated to start Phase II testing in 3Q14; and products for lymphatic filariasis and intestinal worms. Sirturo is a diarylquinoline (DARQ) antibiotic, and rilpivirine is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI). Janssen's participation in the UNITE Project - a consortium working to use mobile technologies to improve HIV outcomes in India - will also be managed by the new division.
Janssen GPH will also help implement pricing and results-based financing models to improve access to its medicines and will be the central point of contact for collaboration with global public health stakeholders. Janssen GPH will be jointly led by Wim Parys, VP of R&D global public health, and Adrian Thomas, VP of global market access, global commercial strategy operations and global public health. ...